The mechanisms of Na+, Cl− and H 2 O transport occur and can now explain previously poorly underalong the various nephron segments are depicted in stood genetic diseases. Figure 1 . These schemes have all evolved from funcIn the proximal tubule inhibitors of carbonic anhydtional studies involving a large spectrum of methodolo-rase can be used to interfere with HCO 3 − absorption. gies [1, 2] . According to these schemes the mechanisms Their effect is usually not very marked because the by which diuretics act in the kidney have been elabor-ensuing acidosis limits their inhibitory effect, and ated [3] and, in fact, in many instances the diuretics because more distal nephron segments, by increasing have been used to clarify the mechanisms depicted in the absorption at these sites, blunt the natriuresis and Figure 1 . All diuretics inhibit the absorption of Na+, diuresis. Genetic defects in carbonic anhydrase II lead Cl− (HCO 3 −) and water by their interaction with to osteopetrosis connected with proximal-tubule-type luminal uptake mechanisms. Although it has been renal tubular acidosis [12] . Another possible target for shown that diuretics can also exert effects on tubule inhibition of proximal tubule absorption is the NHE-3 cells from the peritubule side at high concentrations, Na+/H+ exchanger ( Figure 3A ). Its sensitivity and these effects are probably not of pharmacological relev-selectivity towards amiloride and ethylisopropylamilorance [4] . Diuretics are kidney specific, not because ide is rather poor [13] . However, very recently a new they interfere with proteins specific for the kidney, but derivative benzylguanidino amiloride has been shown because they are secreted into the lumen. This secretion to block this cotransporter with a very high affinity and the water absorption along the nephron contribute [14] . to the high free concentrations of diuretics in tubule
The Na+2Cl−K+ cotransporter of the thick lumen. The mechanism whereby diuretics are secreted ascending limb is depicted schematically in Figure 3B and hence accumulated has been unravelled very [15, 16 ] . This protein is closely related to the Na+Cl− recently [5] [6] [7] [8] [9] and is depicted in Figure 2 . Diuretics cotransporter of the distal tubule [17] . However, it is are taken up across the basolateral membrane by an of clinical relevance that there exists no overlap in anion-(e.g. furosemide, thiazides) or cation-(amilor-terms of pharmacology; loop diuretics bind only to the ide, triamterene) exchanger [5, 6 ] . The exit step into Na+2Cl−K+ cotransporter but not to the Na+Cl− the lumen is not quite clear. It cannot be excluded that cotransporter, and thiazides bind only to latter but not this occurs via ATP-driven pumps such as those to the former. The Na+2Cl−K+ cotransporter exists described for the secretion of bile acids in the canalicu-in two major forms. One is the colonic type and is lar membrane of the hepatocyte [10] . This would be found in almost every tissue. It participates in reguin agreement with old observations that a collapse in latory volume increase in almost every cell and is the secretion of anions is one of the first indicators of involved in the basolateral uptake of Cl− in exocrine proximal tubule damage, and it also explains why the glands. This type of cotransporter has an affinity response to, for example, loop diuretics is attenuated to diuretics (azosemide>bumetanide>furosemide) or abolished in renal failure [11] . Finally any other different from that present in the thick ascending limb organic anion accepted by the basolateral exchanger (bumetanide=torasemide>piretanide>furosemide= will compete with the secretion of diuretics [4] . azosemide) [4, 18] . The other type of Na+2Cl−K+ Recently, the new methodologies of expression clon-cotransporter appears to be specific for the kidney. ing have been used to identify the targets of diuretics Regulation of the Na+2Cl−K+ cotransporter is comat the molecular level. These efforts have been success-plex. Current evidence suggests that it is upregulated, ful and have not only proven the correctness of schemes with activation of proteinkinase A, when cytosolic suggested previously, but have also revealed that gen-Cl−-activity falls and cells shrink [19] [20] [21] [22] . Whether etic defects in these transporters or related proteins all three signalling pathways converge or whether cell shrinkage is the common denominator is currently being studied. . Circles with ATP, (Na+ + K+)-ATPase/H+-ATPase; circles, carrier systems; arrows, ion channels/conductances; CAI, carbonic anhydrase inhibitor; CA, carbonic anhydrase; Furos., furosemide; HCTZ, hydrochlorothiazide; Aldo, aldosterone; R/MR, mineralocorticoid receptor. In all nephron segments the basic pump mechanisms is identical: (Na+ + K+)-ATPase, the luminal uptake mechanisms (Figure 3 ) are divergent. Diuretics usually interfere with these luminal Na+ uptake mechanisms.
toms and signs as treatment by loop diuretics [22, 23] . The other two types of Bartter's syndrome can easily be deduced from Figure 1 . As NaCl absorption in the thick ascending limb depends on the recycling of K+ via luminal ROMK type K+ channels and on the exit via Cl− channels [24, 25] , mutations in these two proteins can lead to Bartter's syndrome types II and III, respectively [23, 25] . The hallmarks of Bartter's syndrome are: volume contraction, hypokalaemia, alkalosis, hypercalciuria and activation of the reninangiotensin-aldosterone system [22] . Depending on the type, the disturbances should be very marked with Fig. 2 . Secretion of diuretics. Circle with ATP, (Na+ + K+)-ATPase; circles, carrier mechanisms; Furos., furosemide; SFA, short fatty acid. Diuretics are taken up by the organic anion (cation) transporter [5, 6 ] . Luminal secretion is possibly via ATPases [10]. These specific secretory processes ensure, together with water absorption, that diuretics accumulate in the lumen fluid. type I. Given that the macula densa cell Na+2Cl−K+ Inhibition by thiazides leads to well-known effects and complications very similar to those caused by loop cotransporter is also affected hyper-reninism should also prevail after adequate volume substitution [26, 27] . diuretics. There is, however, one important difference.
While loop diuretics cause hypercalciuria, thiazides Type II will also be severe. Here, however, K+ losses will probably be less because the primary defect is one cause enhanced absorption of Ca2+. This is explained by two mechanisms ( Figure 1 ): (i) thiazides increase of the ROMK channel. The hyper-reninism will depend exclusively on the degree of volume contraction. Type cytosolic calbindin and this facilitates transcellular Ca2+ absorption [29] , and (ii) thiazides reduce III might be less marked in terms of general symptoms (cf. above), because Cl− can also leave these cells via cytosolic Na+ concentration thus enhancing the driving force for Ca2+ exit via Ca2+/Na+ exchange. the KCl exit ( Figure 1 ). Hyper-reninism might also be less marked than that of type I because these cells Gitelman's syndrome can now be explained as a genetic defect of the Na+Cl− cotransporter. The symptoms would not completely lose their sensory function. All three types will be different from Gitelman's syndrome and signs resemble those of thiazide treatment [12, 23, 28] . (cf. below) because in this syndrome renal Ca2+ excretion is diminished, whereas it is enhanced in Bartter's
The a-subunit of the Na+ channel, present in the collecting duct and probably also in the late proximal syndrome [12, 23, 28] .
The Na+Cl− cotransporter of the distal tubule is tubule [30] is depicted in Figure 3D [31]. The actual Na+ channel, also called the epithelial Na channel shown in Figure 3C . It is obvious that it is closely related to the Na+2Cl−K+ cotransporter discussed ( ENaC ), is probably made up of four subunits: two a, one b and one c. Its function is closely controlled above. The Na+Cl− cotransporter is present in various tissues but little is known on its function in these by aldosterone [32] . This type of channel is also present in other epithelia lining the outer 'surfaces' of our tissues. It is blocked with high affinity by thiazides [17] . 
Introduction Experimental and human data in renal disease
The demonstration that fibrin appeared to be a major The single most conspicuous feature of progressive component of crescentic glomerulonephritis in experiglomerular diseases is an increase in extracellular mental animals and man, led to the supposition that matrix, i.e. scarring. There is often an associated abnormalities in coagulation played an important role increase in the number of cells in the mesangial regions, in acute glomerulonephritis. Based on this hypothesis, leading some to conclude that mesangial cell proliferathere were many attempts to utilize heparin or heparintion plays an important role in the development and like compounds in the treatment of glomerulonephritis progression of glomerulosclerosis. This supposition has (GN ). Encouraging results in experimental animals led been confirmed by recent findings of the presence of to attempts to use heparin in the management of increased mesangial cell turnover in some human dis-rapidly progressive glomerulonephritis [3] . These trials eases and in a large number of experimental animal were stopped due to the side effects of heparin therapy, models, using either histochemical methods or auto-namely the appearance of severe bleeding as a result radiographic techniques [1] . However, ourselves and of anticoagulation. Subsequently it has been generally others have shown that proliferation and glomerulo-agreed that coagulation is very likely a secondary event sclerosis are not necessarily linked [2] . Nonetheless, in GN [1] . these data provided the rationale to examine drugs, More recently, heparin and various fractions of which decrease proliferation and extracellular matrix heparin have been shown to decrease proliferation of synthesis for their potential therapeutic value. Drugs mesangial cells, bind many growth factors, serve as an that would be clinically useful should be orally avail-electron sink, and influence lipid metabolism [4] . As able, reasonably specific, and free of undesirable side these properties of the heparin, and fragments thereof, effects.
have become more evident and heparinoids with The purpose of this editorial is to review the data reduced, or no, anticoagulant activity were prepared, on one class of compounds that fit these requirements, investigators have again begun studying their use in models of kidney and vascular disease. namely sulfated oligosaccharides, including modified fractions of heparin. the nomenclature of heparin derivatives and heparin-like molecules. This may be due to the fact that heparin thickening of the bladder wall due to smooth muscle hyperplasia and scarring. is a large molecule with a protein core to which are attached glycoaminoglycan side chains of variable Finally, PPS has the additional advantage that there is less biological variation between individual batches. composition. The glycosaminoglycan side chains are most often prepared by limited nitrous acid cleavage, It is marketed under the commercial name ElmironB. followed by chromotographic separation. Because of the heterogeneity of the chemical composition of the In vitro data glycoaminoglycan side chains of heparin, the composition of the side chains may vary considerably between
Definition and types of heparinoids
Mesangial cells different preparations. This makes it difficult to make comparisons between different isolates. A further com-Heparin and heparin derivatives, decrease proliferation plication is that the product marketed as heparin is of vascular smooth muscle cells [1, 6 ] . We developed extracted, from either beef or pork tissues and may mesangial cell lines from normal C57/B6 mice that contain other proteoglycans, the most abundant being retain many phenotypic characteristics of the in vivo chondroitin sulfate. Thus, there is considerable vari-situation, including extracellular matrix turnover [7] . ation between individual lots in terms of biological They produce a large amount of type IV collagen and activity and exact chemical content. For this reason, a lesser amount of type I collagen, as well as matrix the material is characterized by international units metalloproteinases (MMP) and tissue inhibitors of based on its anticoagulant activity, not on its molecular matrix metalloproteinases ( TIMPs). mass. For obvious reasons, the degradation products
We examined the responses of these mesangial cells of commercial heparin share this uncertainty as to in vitro to unfractionated heparin and compared it to chemical composition. In addition, heterogeneity PPS [8] . In response to heparin or PPS, mouse mesangbetween different commercially available products is ial cells exhibited a sharp decrease in cell proliferation further accentuated by the fact that low molecular without any change in viability. As noted above, there weight heparins (LMWH ) are modified chemically in was variation between heparin lots, but not between somewhat different ways to either promote or decrease different PPS preparations. Collagen types I and IV their anticoagulant properties.
decreased in the media and cell layer following treatment with PPS, but not with heparin. There was an increase in MMP2 following treatment with both hepHeparin derivatives arin and PPS. Furthermore, both drugs altered the These preparations consist mostly of side chains com-TIMPs profile. TIMP 3 was released in the medium posed of highly sulfated saccharides, and contain most instead of being bound to the MMPs on the cell of the anticoagulant activity. They also include the surface. These data suggest that heparinoids may alter regions containing growth factor and extracellular extracellular matrix turnover, partly by increasing colmatrix molecule binding sites.
lagen degradation, and may therefore be useful in vivo. These data also point out that heparin and PPS have different effects on mesangial cells. It is not yet estabPlant extracts lished how PPS modifies the mitogenic activity of Following the elucidation of the structure of heparin mouse mesangial cells. glycosaminoglycan side chains, there were identified other sources of oligosaccharides, namely those found Mesangial cells from diabetic NOD mice in the plant world. A xylan oligosaccharide, with an approximate molecular mass of 4-6 kDa, was isolated There is still considerable debate as to whether mesangial cells in diabetic animals behave like normal cells from beech trees. Following sulfation, it was found to have little anticoagulant activity, but the sulfated oligo-when they are exposed to high glucose concentrations.
We previously showed that diabetic non-obese diabetic saccharide inhibited thrombus formation. This compound, called pentosan polysulfate or SP54, has been (NOD) mice develop glomerulosclerosis [9] . We also found that mesangial cells isolated from diabetic NOD in clinical use since the 1960s [5] . This compound has often been called a heparinoid. We prefer the term mice (D-NOD-MC ) exhibited a stable phenotypic switch in culture, consisting of increased secretion of sulfated oligosaccharide, referring to its general chemical properties, since the term heparinoid carries the IGF-I and an enhanced growth rate [9] . We measured collagen deposition and the activity of MMP and implication of an anticoagulant action. In fact PPS has 1/15th the anticoagulant activity of unfraction-TIMPs in diabetic and non-diabetic NOD-MC. Total collagen degradation was markedly reduced in ated heparin.
Recently, we have found that PPS shares some of D-NOD-MC and they had a constitutive decrease in MMP-2 and nearly unmeasurable MMP-9 activity. the non-anticoagulant features of unfractionated heparin, and adds others, making it a potentially interes-This was at least partially due to decreased mRNA levels. TIMP levels were slightly decreased in D-NOD ting therapeutic agent [5] . In addition, it has been shown to be effective as an oral agent. The oral form cells. Thus, it is possible that similar changes occur in other models of IDDM in animals or in humans, and is an approved drug for the treatment of interstitial cystitis, a painful bladder condition associated with possibly in other types of renal disease. This question is a current topic of research in our laboratory. Since 40 mg/day. In addition, histologic lesions in the interstitium and glomeruli was markedly decreased in the PPS treatment is associated with a increase in the secretion of MMPs in normal mesangial cells [8], we animals treated with PPS. Interestingly, the intraglomerular capillary hydrostatic pressure and single postulated that it may also increase MMPs in the diabetic cells, providing another avenue for a net nephron GFR were normal in the PPS treated group. decrease in collagen deposition. We found that PPS treatment increased MMP2 activity and released ROP/Os mice TIMP3 into the medium in the diabetic cells. Thus,
We recently described an accelerated model of diabetic PPS treatment appears to result in a net decrease in glomerulosclerosis in ROP Os/+ mice [18] . These mice excess collagen deposition, which is one of the chief have an inborn reduction in nephron number and are features of glomerulosclerosis in diabetic nephropathy.
susceptible to the development of glomerulosclerosis [2, 19] . Diabetes was induced with multiple STZ injec-
Chronic progressive glomerular diseases, in vivo
tions. The mice were maintained for 12 weeks without studies insulin treatment. At sacrifice there were severe glomerular lesions affecting the glomeruli, as well as the Several studies suggest that glomerulosclerosis is interstitium and tubules. One group of mice received decreased by heparin, either intact or non-PPS in the drinking water. We found a decrease in the anticoagulant, and by sulfated oligosaccharides [10] . amount of mesangial sclerosis in the treated mice as This was first shown in the rat ablation model in which well as a diminished amount of type IV collagen the subcutaneous administration of non-anticoagulant mRNA in the glomeruli as measured by RT-PCR. heparin treatment reduced proteinuria and glomerular lesions [11] . In the habu venom model, which is characterized by mesangial and endothelial cell prolif-PTFE grafts in haemodialysis patients eration, subcutaneous heparin treatment also decreased the number of cells in the mesangial region [6 ] . In vitro studies Similarly in the aminonucleoside nephrosis model there Vascular access failure is a major cause of morbidity is a decrease in the glomerular lesions following in patients undergoing maintenance haemodialysis and subcutaneous heparin treatment [12] . Interestingly, the results in large expenditures. Stenosis is the underlying investigators showed that the decrease was not medicause of loss of patency in the majority of failed grafts ated by a change in glomerular haemodynamics. Others and appears to result from proliferation of smooth have also shown a reduction in cell proliferation and muscle cells and an accumulation of extracellular progression of the lesions in a model of diffuse glommatrix. To determine whether this process was amenerulonephritis in the rat thy-1 model, in which the able to pharmacologic intervention and/or prevention, lesions are largely mediated by the influx of activated we obtained material occluding the vascular access macrophages [13] .
from seven patients undergoing surgical revision of the Several recent experimental studies report on the use graft [5] . In all seven patients the outgrowth contained of heparin-derived glycosaminoglycans (GAG). GAG predominantly smooth muscle-like cells, which prodelay the onset of albuminuria in streptozotocin (STZ) duced a large amount of type IV and type I collagen. Sprague Dawley diabetic rats [14] [15] [16] [17] . These data Treatment with PPS inhibited cell proliferation and suggest that heparin and heparin-derived GAG significantly reduced the accumulation of type I and decrease local glomerular lesions through local effects type IV collagen. This was associated with an increase on glomerular cells, rather that than through modificain metalloproteinase-9 (MMP-9) and a shift of tissue tion of renal haemodynamics. One of the current inhibitor of metalloproteinase-3 ( TIMP-3) from the theories entertained by investigators in the field is that cell layer into the medium. These data suggest that heparin and LMWH replace the lost heparan sulfate PPS may have a favorable effect in patients with a at the surface of cells. These data and our own in vitro PFTE graft by decreasing cell proliferation and observations led us to investigate the potential theracollagen deposition. peutic value of PPS.
Experimental animal models
Clinical trials utilizing heparin fractions
5/6 nephrectomy in rats
There are several studies in patients with diabetic nephropathy, each with a small number of subjects. In PPS (100 mg/kg/body weight/day) was administered orally to Wistar male rats (Bobadilla et al. personal one early study, injection of unfractionated heparin or a low molecular weight heparin fraction decreased the communication). The treatment commenced 1 week after 5/6 nephrectomy, and continued for 30 days. albumin excretion rate in 35 patients with IDDM [20] .
Complications led to discontinuation of the study in Proteinuria in the PPS treated group did not differ from non-nephrectomized rats. In contrast, proteinuria four patients, and 12 noted discomfort or bleeding at the injection site, including six treated with the low in the untreated 5/6 nephrectomy group was 
Susceptibility of PKD1 to new mutations polycystic kidney disease (ADPKD). Firstly, from the analysis of germline mutations in PKD1 and PKD2
Given the prevalence of PKD1 in the population and patients, the genetic basis underlying cyst formation in the high rate of new mutation, a question that has ADPKD is now clear. Secondly, the consistent findings arisen is why the human PKD1 gene should be so of somatic PKD1 mutations in PKD1 cyst epithelia is susceptible to new mutations. Preliminary evidence for changing our concepts as to how cysts arise in the first two interesting hypotheses have been presented. The place. Finally, the characterization of PKD1 and first proposes that a unique structural feature of PKD1 PKD2 knockout mice has led to unexpected insights (a long polypyrimidine tract in intron 21) is what into when and how cysts arise in different tissues.
makes the gene more susceptible to mutation [5] . In theory, this tract could promote triplex DNA strands
The spectrum of mutations in PKD1 and PKD2
to form, leading to an increased error rate by several mechanisms. The second hypothesis proposes that gene conversion events (between the HG loci and the PKD1 Detailed mutational analysis of the PKD1 gene has gene) during recombination could lead to an increased proved difficult especially in the region of the gene mutation rate [6 ] . which is duplicated. Nevertheless, most of the duplicEach hypothesis gives rise to a logical prediction. If ated region has now been analysed using methods the first mechanism is operative, further mutational which exploit subtle differences between the HG analysis should reveal a clustering of mutations around (homologous genes) and PKD1 sequences [1, 2] . These intron 21, particularly of gene deletions. If the second studies have given us a better idea of the spectrum of mechanism were true, then a high frequency of identity mutations present in PKD1 families. First of all, they between PKD1 mutations and the corresponding HG have revealed that the majority of mutations detected sequences should be observed. Evidence for the latter are private, indicating a high rate of new mutation.
should be forthcoming with a more complete analysis Secondly, most of the mutations are stops or frameof the duplicated region of PKD1 and the HG loci. shifting changes which would inactivate the gene.
These mechanisms may also help to explain why there Thirdly, no mutation 'hot spot' or genotype-phenotype is an apparent high rate of somatic mutation at PKD1 correlation has been clearly identified in the region (see below). surveyed so far.
Like PKD1, the majority of germline changes in PKD2 are unique inactivating change but unlike Somatic PKD1 mutations in PKD1 cysts PKD1, mutational analysis of the whole of PKD2 has been much more rapid [3] . Evidence for a mutational There is now a consensus that the mutational mechan-'warm spot' (in proximity to a polyadenosine tract) ism in both PKD1 and PKD2 is likely to be a 'loss of has been proposed but like PKD1, no clear genotypefunction' mechanism. However, while the presence of phenotype correlation has been shown, at least for a germline mutation is a necessary first step, it is clearly renal disease severity [4] . Taken together, these results insufficient to trigger cystic behaviour in any given suggest that the first step leading to cyst formation in susceptible cell, especially given the observed focal and sporadic nature of cyst formation. This has in turn led Correspondence and offprint requests to: A. C. M. Ong, Institute of to the idea that an additional event: a second step, is Molecular Medicine, University of Oxford, Headington, Oxford OX3 9DS, UK. required for cysts to form.
The nature of this additional event has been the organs. Like PKD1−/− mice [13] , PKD2−/− mice had numerous kidney and pancreatic cysts in utero but no subject of detailed study [7, 8] and some debate [9] . Attractive evidence has been put forward to suggest liver cysts [14] ; liver cysts were however observed in PKD2+/− mice with increasing age [11] . Although the that this trigger may involve inactivation of the normal polycystin protein by somatic mutation: a 'two hit' full phenotype of PKD1+/− mice has not yet been reported, these observations suggest that the function model, better known among researchers of tumour biology. Using loss of heterozygosity (LOH ) analysis of both polycystin proteins lies more in maintaining biliary ductal organization than in their formation. of PKD1 (a technique utilizing polymorphic microsatellite markers flanking the PKD1 gene), two groups They also imply that the process of cyst formation not only occurs during development but may also occur found LOH involving the normal PKD1 gene in~20% of PKD1 cysts analysed [7, 8] . In addition, a somatic throughout adult life.
In the light of the current evidence, a 'two hit' model mutation consisting of a 2 base pair deletion inactivating the normal PKD1 gene was detected in one cyst, for cyst initiation seems plausible. Such a model is attractive because it could account for the focal nature implying that other smaller changes inactivating PKD1 might be present in LOH negative cysts [8] . More of cyst formation and the phenotypic variability seen between affected individuals within the same family. recently, similar changes have been reported in PKD1 liver cysts [10] .
However, there may be other mechanisms influencing disease severity in ADPKD, albeit less well defined. Perhaps the most striking feature of these findings is that, where it was possible to distinguish between These include the effect of modifier genes and mutant polycystin proteins on expression of the disease the normal and mutant PKD1 alleles, somatic mutations invariably occurred on the background of the phenotype. normal allele. At first glance however, these results appear to conflict with several published studies show-
Infantile-onset PKD1 and modifier genes
ing prominent polycystin-1 expression in PKD1 cystic epithelia [9] . One possible explanation that may reconcile the observations of somatic mutations and per-Very rarely, severely affected infants or children may be born to a mildly affected parent with PKD1. Many sisting polycystin-1 expression is that what is being detected in cyst epithelia is inactivated or non-such cases have been described and a striking difference between these 'early onset' cases and the more typical functional protein. This would be the case if the majority of germline and/or somatic mutations turn adult-onset cases is both the number and the phenotype of renal cysts (mainly glomerular) found in these out to be missense. Analysis of the whole PKD1 gene in individual PKD1 cysts would help clarify the full individuals. It is interesting to note that the increase in disease severity is confined to the kidney. These spectrum of somatic PKD1 mutations. However, given the present difficulties in analysing PKD1 and the cases also resemble homozygous PKD1−/− mice, in terms of their renal phenotype although so far, there similarity in phenotype between the two diseases, a more feasible approach might be to examine PKD2 have been no reports of severely affected offspring born to two affected parents with ADPKD. Typically, cysts for somatic mutations in PKD2.
the child or foetus carries the same stable mutation as the affected parent [15] . Nevertheless, a high recurrence Somatic inactivation in PKD2 knockout mice risk (~45%) has been reported in the subsequent offspring of the affected parent, sometimes with different partners. These findings strongly suggest that Similar to the human disease, heterozygous PKD2 knockout mice (PKD2+/−) develop kidney and liver other inherited factors (so called 'modifying genes' which may be transmitted from the affected parent) cysts [11] . Strikingly, mice heterozygous for an unstable PKD2 allele (which undergoes somatic inac-can modify the rate of cyst formation. If the 'two hit' model is correct, these genes might specifically alter tivation by intragenic homologous recombination to form a true null allele) showed many more cysts than the rate of somatic mutation at PKD1. Alternatively, these genes could encode allelic variants of other mice heterozygous for just a stable PKD2 null mutation. Consistent with this, cysts that develop in proteins which might modulate the activity of polycystin-1 by protein-protein interactions in a cystic PKD2+/− mice showed no polycystin-2 expression by immunohistochemistry. These results contrast with our pathway or complex.
The identification and mapping of these loci would preliminary findings in human PKD2 cystic tissue [12] but the PKD2+/− mice develop relatively few cysts thus provide valuable insights into the mechanism/s governing the initiation and rate of cyst formation. and further analysis may reveal that some cysts express polycystin-2, where somatic missense changes have The influence of genetic background in suppressing or accelerating the rate of cyst formation has been convinoccurred. Overall, these results nevertheless provide strong support for a 'two hit' model of cystogenesis cingly demonstrated in a recessive mouse model of cystic disease ( pcy) and two modifying gene loci in PKD2.
Whilst a cystic phenotype was not unexpected in mapped [16 ] . The availability of PKD1 and PKD2 mutant mice now opens up the possibility of other loci these mutant mice, there was a surprising difference in the rate and timing of cyst formation between different specifically modifying cyst formation in ADPKD being 
Introduction
Argentina, much higher than the 0.6-2.4% reported from other parts of the world. Haemolytic-uraemic syndrome (HUS) was first described and given its name by Swiss haematologists [1] . The first observations on children, most of whom Clinical aspects had reversible acute renal failure, came from Argentina [2] . Subsequent experience showed that the incidence The prevailing form of the disease in Argentina is the of this type of thrombotic microangiopathy ( TMA) epidemic form, caused by the cytotoxin which is prowas higher in Argentina than in any other part of the duced by certain strains of E. coli. Several treatment world. Up to 1993, >5500 cases have been registered trials have been carried out in the acute stage of this in Argentina, the incidence being 2.9/100 000 children, form of HUS; three prospective and controlled studies of <15 years of age (Nephrology Committee of the were executed in children with the diarrhoeal form of Argentine Society of Pediatrics), and these numbers HUS. One was performed at a time when intravascular may even be an underestimate.
coagulation was believed to be responsible for HUS [5] . The authors compared heparin against supportive treatment and found no benefit, while the frequency 
Preventive measures
the histological lesion in the chronic stage resembles those found in experimental and clinical models of Three approaches may diminish the incidence of HUS. hyperfunction of residual nephrons, i.e. focal and First, adequate information must be available to the segmental glomerulosclerosis with mesangial expansion public about the risk of consuming undercooked meat, and focal tubular atrophy and interstitial scarring [14] . unpasteurized cheese and raw milk. Investigators in Second, there is a maladaptive increase of glomerular Argentina noted that a high proportion of patients filtration rate (GFR). For example, we studied 12 came from areas where unprocessed milk is usually children with normal Ccr who had had HUS many consumed [9] . Violation of food hygiene also explains years previously [15] . Four of the 12 were unable to outbreaks in nursing homes or day-care centres.
increase inulin clearance after an acute protein load. A second approach might be prevention through Peak inulin clearance values after a protein load in the development of vaccines directed against E. coli or its 12 patients were significantly lower than in normal toxins. Efforts in this direction are underway in some children (84.9 vs 155 ml/min/1.73 m2, P<0.025). countries with a high prevalence of toxigenic E. coli.
Third, there is a deficit of glomerular permselectivity. A third approach is currently under study in Canada, Some children who had completely normal clinical and i.e. administration of oraly administered toxin-binding laboratory findings years after the acute episode of absorbents [10] .
HUS developed microalbuminuria [16 ] , possibly a reflection of hyperfiltration in residual nephrons with increased filtration of macromolecules. These considerations are important in the develop-
Evolution and sequelae
ment of strategies to halt the late progressive decrease in renal function. Prospective studies currently are In Argentina, recovery from acute renal failure is seen underway to evaluate the effectiveness of restriction of in >95% of children with the epidemic form of HUS. dietary protein intake and of the use of angiotensinHaematological changes are seen only in the acute converting enzyme inhibitors. One question which phase, and sequelae involving the central nervous remains to be answered is: which is the appropriate system (CNS ), pancreas, colon or other organs are time to introduce these measures? Starting treatment infrequent. Chronic renal disease, on the other hand, once microalbuminuria appears may increase the is seen in 35-60% of affected children [11] .
chances of interfering successfully with progression. When large cohorts are followed for more than 1 year after the acute stage, three different outcomes are Transplantation seen. Spizzirri et al. [12] observed 118 children who had HUS in early childhood after >10 years of followup. The first group of 63% had normal urine analysis The registry of the Argentine Society of Pediatrics reveals a prevalence of 16% of HUS among the 178 and creatinine clearance, a second group of 18% had persistent proteinuria with normal creatinine clearance, children entered into chronic renal failure, dialysis or transplantation programmes in 1996. HUS accounts and a third group of 19% had different degrees of decreased glomerular filtration, generally associated for end-stage renal failure in~20% of children requiring renal transplantation in our centre [17] . with proteinuria and hypertension.
After recovery from the acute renal failure, patients The first report of successful transplantation for HUS was published in 1972 by Cerilli [18] , and later may progress to terminal renal failure within 2-5 years, either without having recovered normal Ccr or, in the many centres confirmed the absence of recurrence of the disease in the graft, including in the substantial majority of patients, after having recovered normal serum creatinine levels or creatinine clearance, but number of children with the epidemic diarrhaeal form transplanted in Argentina. This was contradicted by exhibiting persistent proteinuria. This latter group arrive in terminal renal failure after an average of 10 one report from Minneapolis [19] . To resolve this controversy, we reviewed the long-term course of 19 years [13] , but occasionally even after >20 years.
Several findings in the acute stage are predictors of renal grafts in children with the 'classic' epidemic type with a mean follow-up of 5 years with a range of 1-11 late renal prognosis. These are the presence and duration of anuria, hypertension persisting after correction years [20] . Survival of the grafts, maintenance of stable renal function, incidence of acute rejection and prevalof hypervolaemia and severe involvement of the CNS or intestine. These signs are indices of severe and ence of proteinuria and hypertension was not different from those of a randomly selected control group of widespread initial microangiopathy. been reported to range from 0 to 70% [1, 2] . This the blood into Bowman's space. Large and/or anionic molecules are filtered less readily than smaller and/or extreme variability immediately suggests that maybe different disease entities are subsumed under a single cationic compounds (glomerular size and charge selectivity). The initial event in primary FSGS is a loss of histological term.
It is interesting to note that sometimes nephrologists charge selectivity. If the disease is severe, size selectivity can also be impaired. In the latter patients, the rate of base their diagnosis and medical management of patients with glomerular diseases on the histological response to steroid therapy is markedly reduced and prognosis is worse [4, 5] . In secondary FSGS, the initial classification, ignoring important clinical features. Many other members of the medical profession have damage is also a loss of charge selectivity. In addition, however, as proteinuria increases, size selectivity is realized for a long time that tissues in general only have a limited spectrum of reactions to the huge variety impaired gradually over time in these patients.
Treatment with an angiotensin-converting enzyme of insults they may be confronted with. In inflammatory hepatic diseases, histological evaluation of liver (ACE) inhibitor is able to stabilize renal excretory function only as long as proteinuria is due to an tissue is only one part of the diagnostic workup, and hepatologists rarely treat a patient based on the patho-isolated charge selectivity defect as is the case in microalbuminuric patients with diabetic nephropathy. logist's report. In nephrology, unfortunately, the situation is often completely different: the final diagnosis In later stages, appropriate therapy improves size selectivity, but proteinuria is only reduced and the is often made near the morgue, i.e. in the basement of the hospital by a pathologist who all too often is left speed of loss of excretory kidney function is slowed, but not prevented [6 ] . alone by the clinician with little or no information on the patient's actual status or medical history.
The clinical distinction between primary and secondary FSGS is difficult. It is nonetheless essential, since Therefore, one should accept the pathologist's report for what it actually is: the description of an injury immunosuppressive therapy is indicated only in the former condition. A patient with rapid onset of a full pattern rather than the diagnosis of a disease entity. If so, it quickly becomes evident that additional clinical blown nephrotic syndrome is likely to suffer from primary FSGS, whereas a slowly developing proinformation is important to arrive at the correct diagnosis.
teinuric condition in a patient with a typical medical history, that includes conditions summarized in If FSGS is a uniform pattern of injury, that results from a variety of insults, therapeutic regimens have to Table 1 , is more likely to have secondary FSGS.
Evaluation of biopsy material also provides some be individualized.
Rennke and Klein [3] proposed the differentiation distinguishing features. The ultrastructural finding of relatively mild segmental foot process fusion over the between two major disease complexes, both of which are characterized histologically by FSGS on biopsy. non-sclerosed segments with lesser degrees of visceral cell hypertrophy and hyperplasia is indicative of secWhereas the primary form is a disease of the glomerular capillary wall, possibly at the level of the visceral ondary FSGS. In a systematic study of podocyte alterations in primary and secondary forms of FSGS, epithelium, secondary FSGS results from a variety of conditions that promote glomerular capillary hyperten-d'Agati and co-workers noted that the mean percentage of the glomerular surface area affected by foot process sion and increased transcapillary flow rates (see Table 1 ). Clinically, both entities are proteinuric condi-fusion was significantly less in obesity (42±24%) and reflux nephropathy (mean 25%) compared with primtions. An increase of urinary protein excretion is caused by a disturbance of the glomerular permselective prop-ary FSGS (65±23%) [7] . The greatest degree of foot process effacement was observed in the clinically most erties, which determine the ability of the glomerular filter to restrict the passage of macromolecules from malignant forms of FSGS, the collapsing (82±24%) and cellular (87±21%) variants. Unfortunately, with regard to this parameter, remarkable overlap between
